Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Targovax ASA ( (GB:0RIS) ) has issued an update.
Circio Holding ASA announced a change in the file name of their European Single Electronic Format (ESEF) report in their Annual Report. This update, available on their website, reflects the company’s commitment to transparency and regulatory compliance, potentially impacting stakeholder trust and market positioning.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing advanced circular RNA vector expression technology for nucleic acid medicine. Their proprietary circVec technology enhances protein expression significantly compared to traditional mRNA systems, with applications in genetic medicine, cell therapy, and chronic disease. The company is also working on a pan-RAS cancer vaccine, TG01, for KRAS driver mutations, currently in clinical trials for pancreatic, lung cancer, and multiple myeloma.
YTD Price Performance: -93.95%
Average Trading Volume: 23,211
Technical Sentiment Signal: Strong Buy
Current Market Cap: NOK49.56M
Find detailed analytics on 0RIS stock on TipRanks’ Stock Analysis page.